NY AG Takes Up Pay-For-Delay Mantle With Teva Deal

Law360, New York (February 19, 2014, 7:27 PM EST) -- Generic-drug makers Teva Pharmaceuticals USA Inc. and Ranbaxy Pharmaceuticals Inc. on Wednesday promised to put an end to an agreement that kept them from challenging each other's so-called first-filer exclusivity periods, as part of a settlement with New York's attorney general that shows the watchdog's desire to push the reach of pay-for-delay case law.

The pharmaceutical companies agreed to pay the state $300,000 and terminate the agreement, an unusual provision included in a broader deal covering the sale of generic Lipitor, New York Attorney General Eric...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.